Levofloxacin is an antibiotic used to treat bacterial infections such as pneumonia, urinary tract infections, and skin infections. It works by killing bacteria that cause these infections.[2] Levaquin is currently approved and in use across 66 indications[4].[1]
Levaquin is one of 645 small molecule programs targeting Cellulitis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
312 competitors in Prostate Cancer
Levaquin
Rubraca
Truqap
Antiandrogen Therapy
Perflutren Lipid Microspheres
Docetaxel /m²
Pasritamig
Fuzuloparib
Trexall
Jatenzo
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 20, 1996
LEVAQUIN
NDA NDA020635
Dec 20, 1996
LEVAQUIN
NDA NDA020634
Aug 18, 2000
QUIXIN
NDA NDA021199
Mar 1, 2004
IQUIX
NDA NDA021571
Oct 21, 2004
LEVAQUIN
NDA NDA021721
Sources
Details